Literature DB >> 23730026

Hormone replacement therapy: an update.

Suvarna Khadilkar1.   

Abstract

Year:  2012        PMID： 23730026      PMCID： PMC3444558          DOI： 10.1007/s13224-012-0269-y

Source DB:  PubMed          Journal:  J Obstet Gynaecol India        ISSN： 0975-6434


× No keyword cloud information.
  16 in total

1.  Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of The North American Menopause Society.

Authors: 
Journal:  Menopause       Date:  2007 Mar-Apr       Impact factor: 2.953

Review 2.  Long term hormone therapy for perimenopausal and postmenopausal women.

Authors:  Cindy Farquhar; Jane Marjoribanks; Anne Lethaby; Jane A Suckling; Quirine Lamberts
Journal:  Cochrane Database Syst Rev       Date:  2009-04-15

Review 3.  Hormone therapy administration in postmenopausal women and risk of stroke.

Authors:  Christel Renoux; Samy Suissa
Journal:  Womens Health (Lond)       Date:  2011-05

4.  Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.

Authors:  Jacques E Rossouw; Ross L Prentice; JoAnn E Manson; Lieling Wu; David Barad; Vanessa M Barnabei; Marcia Ko; Andrea Z LaCroix; Karen L Margolis; Marcia L Stefanick
Journal:  JAMA       Date:  2007-04-04       Impact factor: 56.272

5.  Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial.

Authors:  Elizabeth Barrett-Connor; Deborah Grady; Andreas Sashegyi; Pamela W Anderson; David A Cox; Krzysztof Hoszowski; Pentti Rautaharju; Kristine D Harper
Journal:  JAMA       Date:  2002-02-20       Impact factor: 56.272

Review 6.  Long-term raloxifene for postmenopausal osteoporosis.

Authors:  Robert R Recker; Bruce H Mitlak; Xiao Ni; John H Krege
Journal:  Curr Med Res Opin       Date:  2011-07-25       Impact factor: 2.580

7.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.

Authors:  S Hulley; D Grady; T Bush; C Furberg; D Herrington; B Riggs; E Vittinghoff
Journal:  JAMA       Date:  1998-08-19       Impact factor: 56.272

8.  Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.

Authors:  Garnet L Anderson; Marian Limacher; Annlouise R Assaf; Tamsen Bassford; Shirley A A Beresford; Henry Black; Denise Bonds; Robert Brunner; Robert Brzyski; Bette Caan; Rowan Chlebowski; David Curb; Margery Gass; Jennifer Hays; Gerardo Heiss; Susan Hendrix; Barbara V Howard; Judith Hsia; Allan Hubbell; Rebecca Jackson; Karen C Johnson; Howard Judd; Jane Morley Kotchen; Lewis Kuller; Andrea Z LaCroix; Dorothy Lane; Robert D Langer; Norman Lasser; Cora E Lewis; JoAnn Manson; Karen Margolis; Judith Ockene; Mary Jo O'Sullivan; Lawrence Phillips; Ross L Prentice; Cheryl Ritenbaugh; John Robbins; Jacques E Rossouw; Gloria Sarto; Marcia L Stefanick; Linda Van Horn; Jean Wactawski-Wende; Robert Wallace; Sylvia Wassertheil-Smoller
Journal:  JAMA       Date:  2004-04-14       Impact factor: 56.272

9.  Menopausal hormone therapy and risk of colorectal cancer.

Authors:  Jill R Johnson; James V Lacey; Deann Lazovich; Melissa A Geller; Catherine Schairer; Arthur Schatzkin; Andrew Flood
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-01       Impact factor: 4.254

10.  Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study.

Authors:  Sally A Shumaker; Claudine Legault; Lewis Kuller; Stephen R Rapp; Leon Thal; Dorothy S Lane; Howard Fillit; Marcia L Stefanick; Susan L Hendrix; Cora E Lewis; Kamal Masaki; Laura H Coker
Journal:  JAMA       Date:  2004-06-23       Impact factor: 56.272
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.